Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telogen effluvium due to recombinant interferon alpha-2b.

A Tosti1, C Misciali, F Bardazzi

  • 1Department of Dermatology, University of Bologna, Italy.

Dermatology (Basel, Switzerland)
|January 1, 1992
PubMed
Summary

Long-term recombinant interferon alpha-2b therapy can cause significant hair loss in patients. This hair loss, a form of telogen effluvium, may resolve even with continued treatment or necessitate its discontinuation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subcutaneous Versus Combined Subcutaneous and Intramuscular Botulinum Toxin for Androgenetic Alopecia: A Randomized Clinical Trial.

Actas dermo-sifiliograficas·2025
Same author

Subcutaneous Versus Combined Subcutaneous and Intramuscular Botulinum Toxin for Androgenetic Alopecia: A Randomized Clinical Trial.

Actas dermo-sifiliograficas·2025
Same author

Trichoscopic Evaluation of Normative Values of Scalp Hair Density in an African Population from Nigeria: A Cross-Sectional Study.

West African journal of medicine·2025
Same author

Subclinical, early hair regrowth in alopecia areata patients under treatment with baricitinib detected by line-field confocal optical coherence tomography evaluation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Onycholemmal horn: A distinctive subungual tumour.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Clinical, epidemiological, trichoscopic and histopathological features of linear morphea on the scalp.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Area of Science:

  • Dermatology
  • Oncology
  • Pharmacology

Background:

  • Recombinant interferon alpha-2b is used for various medical conditions.
  • Hair loss is a potential side effect of some systemic therapies.
  • Telogen effluvium is a common type of non-scarring alopecia.

Purpose of the Study:

  • To investigate the incidence and characteristics of hair loss in patients undergoing long-term recombinant interferon alpha-2b therapy.
  • To assess the relationship between interferon therapy and telogen effluvium.
  • To evaluate the reversibility of hair loss upon discontinuation of the therapy.

Main Methods:

  • Observational study involving 10 patients on long-term recombinant interferon alpha-2b.
  • Clinical assessment of hair loss.

Related Experiment Videos

  • Hair pull tests and trichogram analysis to determine hair shedding patterns.
  • Monitoring of hair loss progression and response to treatment cessation.

    • Main Results:

    • Five out of 10 patients (50%) reported considerable hair loss.
    • Hair pull tests and trichograms indicated telogen effluvium in affected patients.
    • In 2 patients, hair loss improved despite continued therapy.
    • In 3 patients, hair loss persisted until interferon therapy was stopped.
    • Pohl-Pinkus hair constrictions were observed in 2 patients.

    Conclusions:

    • Long-term recombinant interferon alpha-2b therapy is associated with a significant risk of telogen effluvium.
    • The hair loss may be reversible upon discontinuation of interferon therapy.
    • Individual patient responses to interferon-induced hair loss can vary, with some showing improvement while others require cessation of treatment.